Which has preferable earnings and valuation, ZYME or KMDA?

Kamada has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 17.79 -$81.13M -$2.02 N/A Kamada $180.46M 2.82 $20.20M $0.38 23.29

Is ZYME or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Zymeworks' net margin of -405.31%. Kamada's return on equity of 8.37% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% Kamada 11.60% 8.37% 5.85%

Does the media favor ZYME or KMDA?

In the previous week, Kamada had 3 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Kamada's score of 0.56 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KMDA or SEPN?

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.82 $20.20M $0.38 23.29 Septerna $45.95M 39.30 -$48.88M -$0.54 N/A

Is KMDA or SEPN more profitable?

Kamada has a net margin of 11.60% compared to Septerna's net margin of -24.51%. Kamada's return on equity of 8.37% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Septerna -24.51% -9.57% -6.28%

Does the media refer more to KMDA or SEPN?

In the previous week, Kamada had 5 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Kamada and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Kamada's score of 0.56 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STOK or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Stoke Therapeutics' net margin of -753.60%. Kamada's return on equity of 8.37% beat Stoke Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Stoke Therapeutics -753.60% -59.36% -51.46% Kamada 11.60% 8.37% 5.85%

Does the media prefer STOK or KMDA?

In the previous week, Kamada had 6 more articles in the media than Stoke Therapeutics. MarketBeat recorded 7 mentions for Kamada and 1 mentions for Stoke Therapeutics. Kamada's average media sentiment score of 0.56 beat Stoke Therapeutics' score of 0.38 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, NBTX or KMDA?

Kamada has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 45.38 -$27.11M N/A N/A Kamada $180.46M 2.82 $20.20M $0.38 23.29

Is NBTX or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Nanobiotix's net margin of 0.00%. Kamada's return on equity of 8.37% beat Nanobiotix's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Kamada 11.60% 8.37% 5.85%

Does the media prefer NBTX or KMDA?

In the previous week, Kamada had 3 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Nanobiotix. Kamada's average media sentiment score of 0.56 beat Nanobiotix's score of 0.03 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kamada (KMDA) Competitors

$8.85 +0.18 (+2.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.83 -0.02 (-0.23%)

As of 09/18/2026 07:30 PM Eastern

Compare

KMDA vs. ZYME, SEPN, LKFT, STOK, and NBTX

Should you buy Kamada stock or one of its competitors? Kamada's main competitors and comparable companies include Zymeworks (ZYME), Septerna (SEPN), Lakefront Biotherapeutics American Depositary Shares (LKFT), Stoke Therapeutics (STOK), and Nanobiotix (NBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kamada compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Zymeworks presently has a consensus price target of $41.00, suggesting a potential upside of 54.31%. Kamada has a consensus price target of $13.50, suggesting a potential upside of 52.54%. Given Zymeworks' higher possible upside, research analysts clearly believe Zymeworks is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kamada had 3 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Kamada's score of 0.56 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Kamada has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Kamada has a net margin of 11.60% compared to Zymeworks' net margin of -405.31%. Kamada's return on equity of 8.37% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Kamada	11.60%	8.37%	5.85%

Kamada has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kamada beats Zymeworks on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Septerna?

Kamada (NASDAQ:KMDA) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to Septerna's net margin of -24.51%. Kamada's return on equity of 8.37% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Septerna	-24.51%	-9.57%	-6.28%

Kamada has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Septerna has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Kamada presently has a consensus price target of $13.50, indicating a potential upside of 52.54%. Septerna has a consensus price target of $52.44, indicating a potential upside of 35.55%. Given Kamada's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kamada is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29
Septerna	$45.95M	39.30	-$48.88M	-$0.54	N/A

In the previous week, Kamada had 5 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Kamada and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Kamada's score of 0.56 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kamada beats Septerna on 12 of the 17 factors compared between the two stocks.

How does Kamada compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Kamada has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, Kamada had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Kamada's average media sentiment score of 0.56 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.28 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $30.67, indicating a potential upside of 7.41%. Kamada has a consensus target price of $13.50, indicating a potential upside of 52.54%. Given Kamada's stronger consensus rating and higher possible upside, analysts clearly believe Kamada is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kamada. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.41	N/A
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29

Kamada has a net margin of 11.60% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Kamada's return on equity of 8.37% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Kamada	11.60%	8.37%	5.85%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Kamada beats Lakefront Biotherapeutics American Depositary Shares on 13 of the 17 factors compared between the two stocks.

How does Kamada compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Stoke Therapeutics presently has a consensus price target of $44.25, suggesting a potential upside of 55.65%. Kamada has a consensus price target of $13.50, suggesting a potential upside of 52.54%. Given Stoke Therapeutics' higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has lower revenue, but higher earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$3.34	N/A
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29

Kamada has a net margin of 11.60% compared to Stoke Therapeutics' net margin of -753.60%. Kamada's return on equity of 8.37% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Kamada	11.60%	8.37%	5.85%

Stoke Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Kamada has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

20.4% of Kamada shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Kamada had 6 more articles in the media than Stoke Therapeutics. MarketBeat recorded 7 mentions for Kamada and 1 mentions for Stoke Therapeutics. Kamada's average media sentiment score of 0.56 beat Stoke Therapeutics' score of 0.38 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kamada beats Stoke Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Kamada compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Kamada has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	45.38	-$27.11M	N/A	N/A
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kamada has a net margin of 11.60% compared to Nanobiotix's net margin of 0.00%. Kamada's return on equity of 8.37% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Kamada	11.60%	8.37%	5.85%

Nanobiotix has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Kamada has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Nanobiotix currently has a consensus target price of $46.67, suggesting a potential upside of 41.20%. Kamada has a consensus target price of $13.50, suggesting a potential upside of 52.54%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kamada had 3 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Nanobiotix. Kamada's average media sentiment score of 0.56 beat Nanobiotix's score of 0.03 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kamada beats Nanobiotix on 11 of the 13 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$508.92M	$3.90B	$7.24B	$13.19B
Dividend Yield	1.44%	3.64%	2.57%	12.81%
P/E Ratio	23.29	14.23	274.93	25.38
Price / Sales	2.82	1,419.61	646.01	89.45
Price / Cash	14.49	108.90	76.25	51.42
Price / Book	1.89	15.45	10.46	6.33
Net Income	$20.20M	-$22.86M	$3.49B	$358.33M
7 Day Performance	11.74%	-1.21%	0.59%	1.12%
1 Month Performance	10.35%	-3.29%	-1.74%	-2.39%
1 Year Performance	28.08%	37.74%	18.13%	5.35%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.9687 of 5 stars	$8.85 +2.1%	$13.50 +52.5%	+28.1%	$508.92M	$180.46M	23.29	462	News Coverage Analyst Forecast
ZYME Zymeworks	2.9047 of 5 stars	$26.14 -2.7%	$41.00 +56.9%	+63.5%	$1.85B	$105.96M	N/A	264	Analyst Forecast
SEPN Septerna	3.0057 of 5 stars	$39.32 -0.6%	$52.44 +33.4%	+146.4%	$1.84B	$98.88M	N/A	130
LKFT Lakefront Biotherapeutics American Depositary Shares	1.0616 of 5 stars	$27.75 +3.9%	$30.67 +10.5%	-16.4%	$1.83B	$1.26B	N/A	1,310	Analyst Downgrade High Trading Volume
STOK Stoke Therapeutics	3.0372 of 5 stars	$28.15 -4.9%	$44.25 +57.2%	+24.1%	$1.82B	$184.42M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors